Show simple item record

dc.contributor.authorHarrington, KJen_US
dc.contributor.authorMichielin, Oen_US
dc.contributor.authorMalvehy, Jen_US
dc.contributor.authorPezzani Grüter, Ien_US
dc.contributor.authorGrove, Len_US
dc.contributor.authorFrauchiger, ALen_US
dc.contributor.authorDummer, Ren_US
dc.date.accessioned2017-09-06T13:44:35Z
dc.date.issued2017-01en_US
dc.identifier.citationOncoTargets and therapy, 2017, 10 pp. 3867 - 3880en_US
dc.identifier.issn1178-6930en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/813
dc.identifier.eissn1178-6930en_US
dc.identifier.doi10.2147/ott.s133699en_US
dc.description.abstractTalimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene laherparepvec is a genetically modified viral therapy, and its handling needs special attention due to its deep freeze, cold-chain requirements, its potential for viral shedding, and its administration by direct intralesional injection. This review provides a practical overview of handling, storage, and administration procedures for this agent in Europe. Talimogene laherparepvec vials should be transported/stored frozen at a temperature of -90°C to -70°C, and once thawed, vials must not be refrozen. Universal precautions for preparation, administration, and handling should be followed to avoid accidental exposure. Health care providers should wear personal protective equipment, and materials that come into contact with talimogene laherparepvec should be disposed of in accordance with local institutional procedures. Individuals who are immunocompromised or pregnant should not prepare or administer this agent. Talimogene laherparepvec is administered by intralesional injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound. Treatment should be continued for ≥6 months. As with other immunotherapies, patients may experience an increase in the size of existing lesion(s) or the appearance of new lesions (ie, progression) prior to achieving a response ("pseudo-progression"). As several health care professionals (eg, physicians [dermatologists, surgeons, oncologists, radiologists], pharmacists, nurses) are involved in different stages of the process, there is a need for good interdisciplinary collaboration when using talimogene laherparepvec. Although there are specific requirements for this agent's storage, handling, administration, and disposal, these can be effectively managed in a real-world clinical setting through the implementation of training programs and straightforward standard operating procedures.en_US
dc.formatElectronic-eCollectionen_US
dc.format.extent3867 - 3880en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleA practical guide to the handling and administration of talimogene laherparepvec in Europe.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.2147/ott.s133699en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0en_US
rioxxterms.licenseref.startdate2017-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfOncoTargets and therapyen_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume10en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorHarrington, Kevinen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/